Jak za nás rozhoduje naše břicho, i když si to nechceme piznť. Ďakujem. A priatelia, niečo vo vás je a je to zhruba takto dlhé.Je to vaše črevo. Nás učili na základnej škole. Črevo je od toho, aby sme doňho vkladali potravu.Ono nám vytiahlo živiny a mohli sme existovať. Ale v tom čreve sa toho deje omnoho omnoho viac. A o čom ja budem hovoriť dneska, sú tie miliardy miniatúrnych organizmov, ktoré v ňom žijú.Červná mikroflóra, mikrobióm. Na celom vašom tele, vo vlasoch, v ústach, medzi prstami na nohách žijú ...

Gut-Brain Axis & Mental Health - The gut-brain axis enables direct influence from the gut on the brain, affecting physical and emotional states [3] - Gut bacteria produce approximately 90% of the body's serotonin, a key hormone for happiness and emotional stability [4] - Gut bacteria imbalance, known as dysbiosis, can lead to anxiety, depression, and cognitive decline [5] Impact of Diet & Lifestyle - Poor diet, stress, and antibiotics can cause gut bacteria imbalance [4] - Foods like yogurt, sauerkraut, kimchi, and kefir are excellent sources of probiotics, restoring gut balance and supporting mental health [6] - Exercise encourages beneficial bacteria growth and increases intestinal mobility, benefiting both body and mind [6][7] - Diets high in sugar and processed foods can lead to gut bacteria imbalance [8][9] - Stress management and adequate sleep are vital for maintaining healthy gut bacteria and overall well-being [7][8] Probiotics & Prebiotics - Prebiotics, found in foods like bananas, onions, garlic, and asparagus, feed beneficial gut bacteria [5][6] - Probiotic supplements may enhance mood and lessen anxiety, but using the correct strains is crucial [10]

Company Overview - Lifeway Foods, Inc. is a leading U.S. supplier of kefir and fermented probiotic products, recognized as one of Forbes' Best Small Companies [3] - The company produces a variety of products including drinkable kefir, cheeses, and a ProBugs line for kids, with distribution across the U.S., Mexico, Ireland, South Africa, UAE, and France [3] Product Highlights - Lifeway's Berry Blast Probiotic Smoothie + Collagen has won Good Housekeeping's 2025 Snack Awards, highlighting its market recognition [1] - The smoothie contains 5 grams of hydrolyzed collagen per bottle, supporting skin health and joint support, along with 12 live and active probiotic cultures and billions of beneficial CFUs [1][2] - The product is lactose-free and gluten-free, catering to rising consumer demand for functional dairy products [2] Market Trends - The introduction of the Probiotic Smoothie + Collagen line, which includes flavors like Matcha Latte and Tropical Fruit, responds to increasing consumer interest in gut-skin health connections [2]

Company Acquisition - The Akkermansia Company (TAC) has been acquired by Danone, a leading global food and beverage company [1] Product Development - TAC's founding scientists discovered the biotic strain Akkermansia muciniphila MucT in 2004, demonstrating its ability to reinforce the gut barrier, reduce inflammation, and counteract metabolic disorders such as obesity, diabetes, and cardiovascular disease [2] - The company holds broad patents protecting the use of the Akkermansia species, including the pasteurized version MucT, which is its most bio-efficacious form [2] Market Expansion - TAC is expanding its business into key markets in Europe, North America, and Asia, aiming to accelerate global growth of the pasteurized Akkermansia muciniphila MucT strain [3] - The CEO of TAC expressed excitement about joining Danone, highlighting the resources that will facilitate faster brand development [3] Vision and Goals - TAC's Chief Technology Officer emphasized the goal of providing billions of consumers with improved metabolic health through Akkermansia [4] - The company aims to shift the focus of microbiome health from symptoms to root causes, positioning itself as a leader in next-generation probiotic and postbiotic supplements [5]

Core Insights - Lifeway Foods, Inc. has announced the establishment of National Kefir Day, to be celebrated annually on June 18, recognizing the cultural and nutritional significance of kefir and the company's legacy in promoting gut health for nearly 40 years [1][3] Group 1: Event Details - The official proclamation will occur at a press event in Chicago, featuring remarks from key leaders in government, medicine, and nutrition, including Lifeway's President and CEO Julie Smolyansky [2] - The event will highlight the connection between gut health and chronic disease prevention, with Smolyansky discussing kefir's role in supporting immunity and overall wellness [2] Group 2: Company Initiatives - Lifeway Foods aims to promote gut health, sustainability, and mindful nutrition through National Kefir Day, reflecting a cultural shift towards fermented foods for better health [3] - The company will distribute free Lifeway Kefir samples in major cities including Chicago, New York, Los Angeles, and Miami on June 18, and will sponsor a drone show over Lake Michigan to celebrate Chicago as the "Kefir Capital of the World" [5] Group 3: Marketing and Engagement - Lifeway is launching a tattoo challenge as part of the National Kefir Day festivities, rewarding fans who showcase their love for the brand with a year of free kefir [6] - Participants are encouraged to share photos or videos of their Lifeway-inspired tattoos on social media platforms [7] Group 4: Company Background - Lifeway Foods is recognized as a leading supplier of probiotic kefir and has expanded its product line to include various cheeses and a ProBugs line for children, with products sold in multiple countries [8]

Core Insights - Northstrive Biosciences Inc. has completed a Phase I strategic research and literature synthesis for its first-in-class oral myostatin-engineered probiotic, EL-22, aimed at addressing muscle-wasting conditions [1][7] - The analysis, conducted with Yuva Biosciences, provided insights into EL-22's mechanism of action and its potential to meet critical needs in muscle-wasting conditions such as GLP-1-associated atrophy and age-related sarcopenia [1][7] Company Overview - Northstrive Biosciences Inc. is a biopharmaceutical company under PMGC Holdings Inc., focusing on developing innovative aesthetic medicines [4] - The lead asset, EL-22, utilizes a myostatin-engineered probiotic approach to help preserve muscle during weight loss treatments, particularly with GLP-1 receptor agonists [4] Product Highlights - EL-22 employs a myostatin-engineered probiotic strategy to combat obesity-related muscle loss during weight loss treatments, offering a patient-friendly oral delivery method [2][4] - The product is designed to induce an immune response against myostatin, a key regulator of muscle growth, using genetically engineered Lactobacillus casei [2] Research Findings - The report highlights significant effects of EL-22 in mdx mice, including improvements in antibody production, serum creatine kinase levels, body weight, motor function, and muscle histology [7] - EL-22's unique oral vaccine approach distinguishes it from traditional systemic antibody or gene therapy methods, aiming to stimulate both mucosal and systemic immunity against myostatin [7] Market Positioning - With the rise of GLP-1 receptor agonists in obesity and diabetes treatment, EL-22 is strategically positioned to address the associated muscle loss concerns [7] - Northstrive plans to initiate a Phase 2 proof-of-concept trial targeting GLP-1 users and engage in regulatory discussions to advance EL-22 towards an IND filing in the U.S. [7]

Lifeway Foods (LWAY) Q1 2025 Earnings Call May 13, 2025 09:00 AM ET Company Participants Julie Smolyansky - CEO, President, Secretary & Chairperson of the Board Operator Good morning. Welcome to LifeWay Foods Fourth Quarter and Full Year twenty twenty four Conference Call. On the call with me today is Julie Smolansky, President and Chief Executive Officer. By now, everyone should have access to the press release that went out this morning. If you have not received the release, it is available on the Investo ...

Lifeway Foods (LWAY) Q1 2025 Earnings Call May 13, 2025 09:00 AM ET Speaker0 Good morning. Welcome to LifeWay Foods Fourth Quarter and Full Year twenty twenty four Conference Call. On the call with me today is Julie Smolansky, President and Chief Executive Officer. By now, everyone should have access to the press release that went out this morning. If you have not received the release, it is available on the Investor Relations portion of LifeWay's website at www.lifewayfoods.com. A recording of this call wi ...

Core Viewpoint - Northstrive Biosciences Inc., a subsidiary of PMGC Holdings Inc., has filed four novel patent applications for its candidates EL-22 and EL-32, targeting both the animal market and muscle loss treatment in obese patients, either as standalone therapies or in combination with GLP-1 receptor agonists [1][2][3]. Patent Applications - The four patent applications filed include: - EL-32 in the USA and Korea for treating sarcopenia with transformed microorganisms [4]. - EL-22 in the USA for treating muscle loss in obese patients and in combination with GLP-1 receptor agonists [4][5]. - EL-22 for encouraging muscle growth in animals [5]. - EL-32 as a pharmaceutical composition for treating muscle loss due to obesity and as a combination therapy utilizing GLP-1 receptor agonists [5][6]. Intellectual Property Portfolio - Northstrive's patent portfolio now consists of 8 patent applications and 5 issued patents, providing protection in key markets including the USA, Japan, China, and Korea [3][7]. Company Overview - Northstrive Biosciences Inc. focuses on developing innovative solutions for obesity treatment, particularly through preserving muscle mass during weight loss [7]. - PMGC Holdings Inc. manages a diversified portfolio through strategic acquisitions and investments across various industries, including biopharmaceuticals [8].

Core Viewpoint - Northstrive Biosciences Inc., a subsidiary of PMGC Holdings Inc., has filed four novel patent applications for its candidates EL-22 and EL-32, targeting both the animal market and muscle loss treatment in obese patients, either as standalone therapies or in combination with GLP-1 receptor agonists [1][2][3]. Patent Applications - The four patent applications filed include compositions for treating sarcopenia and muscle loss in both humans and animals, emphasizing the engineered probiotic platform aimed at obesity care [2][5]. - The patents cover various formulations, including a fusion protein of Myo-2 for treating muscle loss in obese patients and animal feed additives to encourage muscle growth [4][5]. Intellectual Property Portfolio - Northstrive's patent portfolio now consists of 8 patent applications and 5 issued patents, providing protection in key markets such as the USA, Japan, China, and Korea [3][4]. - The newly filed patents are expected to strengthen the company's intellectual property position as it seeks to transform obesity care standards and enter the animal health market [3][4]. Company Overview - Northstrive Biosciences Inc. focuses on developing innovative solutions for obesity, particularly through preserving muscle mass during weight loss treatments [7]. - PMGC Holdings Inc. manages a diversified portfolio through strategic acquisitions and investments across various industries, including biopharmaceuticals [8].